Sangamo enters into asset sale agreements with Lilly and Astellas

Click here to view

Additional information about the Chapter 11 reorganization and asset sales is available through Sangamo's noticing agent at https://www.veritaglobal.net/SangamoTherapeutics.

Presentation

Durable, Multiplexed Cell Engineering Using Zinc Finger–Guided Transcriptional Regulators Delivered via a Single Viral Particle

Download PDF